摘要
目的统计康柏西普与雷珠单抗治疗年龄相关性黄斑变性的临床疗效。方法选取2020年1月至2021年3月本院收治的46例年龄相关性黄斑变性患者作为研究对象,按入院顺序分为实验组和对照组,每组23例。实验组采用康柏西普治疗,对照组采用雷珠单抗治疗。比较两组治疗前后视力值、视网膜厚度及脉络膜新生血管(CNV)渗漏改善情况。结果治疗前,两组视力值及视网膜厚度比较差异无统计学意义;治疗3个月后,两组视力值均高于治疗前,视网膜厚度均小于治疗前,且实验组视力值高于对照组,视网膜厚度小于对照组,差异有统计学意义(P<0.05)。治疗3个月后,两组CNV渗漏改善总有效率比较差异无统计学意义。结论康柏西普治疗年龄相关性黄斑变性患者疗效显著,可有效改善患者视力、视网膜厚度,控制CNV渗漏情况,值得临床推广应用。
Objective To explore the efficacy of conbercept and ranibizumab in the treatment of age-related macular degeneration.Methods 46 patients with age-related macular degeneration admitted to our hospital from January 2020 to March 2021 were enrolled as research subjects,and they were divided into experimental group and control group according to the order of admission,with 23 cases in each group.The experimental group was treated with compacept,and the control group was treated with ranibizumab.The improvement of visual acuity value,retinal thickness and choroidal neovascularization(CNV)leakage before and after treatment was compared between the two groups.Results Before treatment,there was no significant difference in visual acuity value and retinal thickness between the two groups;after 3 months of treatment,the visual acuity values of both groups were higher than before treatment,and the retinal thickness was smaller than that before treatment,the visual acuity value of the experimental group was higher than that of the control group,and the thickness of the retina was smaller than that of the control group,and the differences were statistically significant(P<0.05).After 3 months of treatment,there was no significant difference in the overall effective rate of CNV leakage improvement between the two groups.Conclusion Conbercept is effective in the treatment of patients with age-related macular degeneration,which can effectively improve the visual acuity,retinal thickness,and control the leakage of CNV,which is worthy of clinical application.
作者
周超
张平华
易蓓
ZHOU Chao;ZHANG Pinghua;YI Bei(Department of Ophthalmology,The First People's Hospital of Fuzhou,Fuzhou,Jiangxi,344000,China)
出处
《当代医学》
2022年第34期160-162,共3页
Contemporary Medicine
基金
抚州市指导性科技计划项目(抚科计字[2020]10号,第34项)。
关键词
康柏西普
雷珠单抗
年龄相关性黄斑变性
血管内皮生长因子
脉络膜新生血管
Conbercept
Ranibizumab
Age-related macular degeneration
Vascular endothelial growth factor
Choroidal neovascularization
